Ulcerative colitis increases the risk of atrioventricular block: evidence from a Mendelian randomized analysis

Wanqiong Shu1, Guanghong Huang2

  • 1Affiliated Guangdong Hospital of Integrated Traditional Chinese and Western Medicine of Guangzhou University of Chinese Medicine, No.16, Guicheng South Fifth Road, Nanhai District, Foshan, 528200, China.

Scientific Reports
|April 8, 2025
PubMed

Insights

Inflammatory bowel disease (IBD), specifically ulcerative colitis (UC), may increase the risk of developing atrioventricular block (AVB). This study used Mendelian randomization to explore the causal link between IBD and arrhythmia.

Area of Science:

  • Cardiovascular Medicine
  • Gastroenterology
  • Genetics

Background:

  • Growing evidence links inflammatory bowel disease (IBD) to cardiovascular disease.
  • The specific relationship between IBD and cardiac arrhythmias remains largely undetermined.

Purpose of the Study:

  • To investigate the potential causal relationship between inflammatory bowel disease (IBD) and specific arrhythmia phenotypes using Mendelian randomization.
  • To assess the association between IBD subtypes (ulcerative colitis and Crohn's disease) and atrioventricular block (AVB) and paroxysmal tachycardia (PTA).

Main Methods:

  • Two-sample Mendelian randomization analysis utilizing single nucleotide polymorphisms (SNPs) associated with IBD (including UC and CD) as instrumental variables.
  • Outcome data for atrioventricular block (AVB) and paroxysmal tachycardia (PTA) were analyzed using inverse variance weighting and other MR methods.
  • Sensitivity analyses, including heterogeneity, pleiotropy, and leave-one-out analyses, were performed to ensure result validity, with MR-Egger regression and weighted median methods employed.

Main Results:

  • A significant association was found between ulcerative colitis (UC) and an increased risk of atrioventricular block (AVB) (OR 1.178, P=0.000828).
  • MR-Egger regression and weighted median methods confirmed this association.
  • Verification analysis using an independent dataset corroborated the findings (OR 1.048, P=0.022947).

Conclusions:

  • Ulcerative colitis (UC) may be associated with a heightened risk of developing atrioventricular block (AVB).
  • These findings suggest a potential role for inflammatory bowel disease (IBD) in increasing the risk of cardiac arrhythmias.
  • Further research is warranted to elucidate the mechanisms underlying this association.

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
98
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
729
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
407
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
846
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
665